CVRx, Inc. Class Action Lawsuit - CVRX

The filed complaint alleges that CVRx, Inc made materially false and/or misleading statements and/or failed to disclose that: (a) to induce sales growth, CVRx and/or its employees were engaged in illegal and unsustainable sales practices, including improperly marketing Barostim, offering or paying kickbacks, and providing false information to government health insurance programs in violation of the False Claims Act (“FCA”) and Anti-Kickback Statute (“AKS”); (b) CVRx’s revenues were in part the product of such unlawful conduct and thus unsustainable; (c) the illegal sales and marketing activities increased the risk of criminal and civil liability; and (d) as a result of the foregoing, defendants’ public statements, including the Company’s reported revenue, purported growth drivers, compliance with the FCA and AKS, the effectiveness of its patient access and reimbursement strategy, and the effectiveness of CVRx’s internal controls over financial reporting were materially false and misleading at all relevant times.

Investors who purchased or otherwise acquired CVRx, Inc. securities within the class period described above and suffered losses may be eligible.

If you suffered a loss in CVRx, Inc. during the relevant time frame or pursuant to the relevant offering(s), you have until January 8, 2027 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Key Facts About CVRx, Inc. (NASDAQ: CVRX)

●       The Allegation: The complaint alleges that CVRx and its executives made materially false and misleading statements by concealing that the company allegedly used illegal and unsustainable sales practices, including improperly marketing its Barostim device, offering or paying kickbacks, and providing false information to government health insurance programs, and by misrepresenting the progress of its sales force transformation while turnover remained unstable and productivity lagged.

●       The Stock Drop: On August 7, 2026, CVRX fell $3.55 per share (60%) to close at $2.39 per share, after the company disclosed a Department of Justice civil investigative demand under the False Claims Act and cut its outlook on weak sales force productivity; earlier, on April 8, 2025, CVRX fell $5.34 per share (46%) to close at $6.20 per share following a preliminary revenue shortfall tied to sales force problems; and on May 9, 2025, CVRX fell $3.01 per share (39%) to close at $4.77 per share after further disclosures about sales force productivity issues.

●       Class Period & Defendants: The class period runs from July 25, 2023, through August 6, 2026, inclusive. The named defendants are CVRx, Inc., Kevin Hykes (President and Chief Executive Officer since February 2024), Nadim Yared (President and Chief Executive Officer through February 2024), Jared Oasheim (Chief Financial Officer), and Robert John (Chief Revenue Officer from June 2024 to August 2026).

●       Lead Plaintiff Deadline: January 8, 2027. Investors who wish to seek appointment as lead plaintiff must apply by the deadline.

CVRx Class Action Summary
Company	CVRx, Inc. (NASDAQ: CVRX)
Lead Plaintiff Deadline	January 8, 2027
Class Period	July 25, 2023 – August 6, 2026
Stock Drop	August 7, 2026 – CVRX fell $3.55 (60%) to $2.39; April 8, 2025 – CVRX fell $5.34 (46%) to $6.20; May 9, 2025 – CVRX fell $3.01 (39%) to $4.77

Introduction

A securities class action has been filed against CVRx, Inc. (NASDAQ: CVRX). The named plaintiff is the Oklahoma Police Pension and Retirement System. The case covers investors who bought CVRx common stock from July 25, 2023, through August 6, 2026.

The complaint alleges that CVRx made materially false and misleading statements about its business and sales practices. It claims the company hid that some of its revenue came from illegal sales and marketing conduct that could not last. The filing also alleges that CVRx misstated the progress of its sales force rebuild, when turnover stayed high and new reps were not yet productive.

CVRx shares fell sharply following the disclosures identified in the complaint. CVRx stock fell 46% in April 2025 and 39% in May 2025 on sales force news. The stock then fell 60% on August 7, 2026, after the company revealed a Department of Justice investigation and cut its outlook.

Company Profile

CVRx, Inc. is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular disease. Its sole product, Barostim, is an implantable device and the first FDA-approved medical technology that uses neuromodulation to improve the symptoms of patients with heart failure with reduced ejection fraction. CVRx is headquartered in Minneapolis, Minnesota, and its common stock trades on the Nasdaq under the symbol CVRX.

Class Period

July 25, 2023–August 6, 2026

Investors who purchased or otherwise acquired CVRx, Inc. (CVRX) common stock during the Class Period may be eligible to seek recovery under the federal securities laws.

Allegations

The complaint centers on CVRx, a medical device company whose entire business depends on sales of a single product, Barostim, to hospitals that bill government and commercial payors for the implant procedure. During the class period, CVRx and certain executives attributed the company's revenue growth to factors including expansion into new sales territories, increased physician and patient awareness, and the effectiveness of its in-house market access and reimbursement efforts. The company also stated that it trained its sales force against off-label promotion and that it was in compliance with healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute.

According to the complaint, those representations were materially false and misleading. The lawsuit alleges that, to induce sales growth, CVRx and its employees engaged in illegal and unsustainable sales practices, including improperly marketing Barostim, offering or paying kickbacks to healthcare providers, and providing false information to government health insurance programs in violation of the False Claims Act and the Anti-Kickback Statute. As a result, the complaint alleges, a portion of CVRx's reported revenue was the product of unlawful conduct and was therefore unsustainable, and the company's compliance representations and the effectiveness of its internal controls over financial reporting were false.

The complaint further alleges a separate but related set of misstatements about the company's sales force. CVRx repeatedly told investors that it had stabilized its sales organization, that turnover had returned to normal levels, and that its newer representatives were becoming productive. The lawsuit claims these assurances were false because sales force turnover had not been stabilized, productivity remained materially below expectations, and a significant portion of the sales force was inexperienced and required extended training and ramp time before it could meet revenue projections.

The filing alleges that the Officer Defendants knew or recklessly disregarded these facts because of their senior positions and access to material nonpublic information, and that they were motivated to keep the company's share price artificially high. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.

The Truth Emerges

The complaint alleges that information concerning the alleged misstatements reached the market in stages. On April 7, 2025, after the close, CVRx announced preliminary first-quarter results that fell short of expectations and attributed the miss in part to sales force turnover and productivity problems. The stock fell 46% the next day, from $11.54 to $6.20 per share. On May 8, 2025, the company revealed more detail about the severity of the sales force realignment, disclosing that 25% of its territory managers had been hired between December and March, and shares fell another 39%, from $7.78 to $4.77 per share.

The most significant disclosure came on August 6, 2026, after the market close. CVRx filed a Form 10-Q revealing that on May 14, 2026, it had received a civil investigative demand from the U.S. Department of Justice in connection with a False Claims Act investigation into whether the company caused the submission of false claims to government health insurance programs by improperly marketing its device, offering or paying kickbacks to healthcare providers, or providing false information to government health insurance programs. On the same day, the company cut its outlook, citing fewer sales territories than anticipated, lower sales force productivity, and a prolonged challenge with one of its largest payors.

The complaint alleges these revelations directly contradicted the company's prior assurances that it complied with healthcare fraud and abuse laws and that it had stabilized and strengthened its sales organization. Analysts reacted sharply, with one firm downgrading the stock and others noting that the sales force disruption had been a recurring concern. The complaint alleges that these disclosures revealed previously undisclosed problems with the company's sales practices, compliance representations, and sales force productivity.

Market Reaction

The market reaction to the series of disclosures was severe. Following the April 7, 2025 preliminary results, CVRX stock fell $5.34 per share, or 46%, to close at $6.20 on April 8, 2025, on heavy volume. After the company disclosed further sales force productivity problems on May 8, 2025, the stock dropped an additional $3.01 per share, or 39%, to close at $4.77 on May 9, 2025, again on heavy volume.

The largest decline followed the August 6, 2026 disclosure of the Department of Justice civil investigative demand and the reduced outlook. CVRX stock fell $3.55 per share, or 60%, from $5.94 on August 6, 2026, to close at $2.39 on August 7, 2026, on heavy volume. A subsequent announcement that the company's Chief Revenue Officer would depart contributed to a further decline of $0.33 per share, or 11%, to close at $2.75 on August 17, 2026.

Next Steps

●       Lead Plaintiff Deadline: January 8, 2027

●       After the lead plaintiff deadline, the Court will consider any lead plaintiff motions. 

●       Defendants may file a motion to dismiss.

●       If the case proceeds, the Court may later consider class certification.

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. Prior results do not guarantee similar outcomes.